http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005074641-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76ba102ea9c02b6633d64bf09c5b89a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94dc5053a40666411dbfe9318e5ea268 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1822f87c9d2380fcee2652a32bb77b6 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-944 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-94 |
| filingDate | 2005-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9578422a6df13799fa288f2900a14774 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c92822fadc182c283bf2d284b64c81d |
| publicationDate | 2006-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2005074641-A3 |
| titleOfInvention | Variant neuronal nicotinic alpha-7 receptor and methods of use |
| abstract | The present invention relates to a variant of the nicotinic acetylcholine receptor (nAChR) α7 subunit having a substitution within its second transmembrane (TM2) domain. Specifically, the sixth amino acid position within the TM2 domain has the point mutation T→ S, such that threonine-244 becomes serine-244. Advantageously, the α7 variant of the present invention retains the essential drug sensitivities of the wild-type α7 receptor, but does not exhibit the response-limiting form of fast desensitization. Therefore, the α7 variant is a 'gain of function' mutant that is particularly useful for testing new pharmacological agents. The present invention includes the T6'S variant TM2 domain, T6'S variant α7 subunit, and T6'S variant nACh receptor polypeptides, polynucleotides encoding these polypeptides, recombinant hosts expressing these polynucleotides, and assays utilizing the T6'S variant TM2 domain, T6'S variant α7 subunit, and/or T6'S variant nACh receptor. |
| priorityDate | 2004-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID187 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395454 |
Total number of triples: 24.